Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
TREATMENT OF UNRESECTABLE HEPATOCELLULAR-CARCINOMA WITH A COMBINATIONOF HUMAN RECOMBINANT ALPHA-2B INTERFERON AND DOXORUBICIN - RESULTS OFA PILOT-STUDY
Autore:
LOTZ JP; GRANGE JD; HANNOUN L; BOUDGHENE F; AMIOT X; LAMARQUE D; ANDRE T; ESTESO A; BELLAICHE A; BOULEUC C; BODIN F; PARC R; BIGOT JM; IZRAEL V;
Indirizzi:
HOP TENON,SERV CLIN ONCOL,4 RUE CHINE F-75970 PARIS 20 FRANCE HOP TENON,SERV GASTROENTEROL F-75970 PARIS 20 FRANCE HOP TENON,SERV RADIOL F-75970 PARIS 20 FRANCE HOP ST ANTOINE,SURG SERV F-75012 PARIS FRANCE
Titolo Testata:
European journal of cancer
fascicolo: 9, volume: 30A, anno: 1994,
pagine: 1319 - 1325
SICI:
0959-8049(1994)30A:9<1319:TOUHWA>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHASE-I; POSITIVE INTERACTIONS; LEUKOCYTE INTERFERON; CLONOGENIC-ASSAY; PLUS DOXORUBICIN; CANCER-TREATMENT; ADRIAMYCIN; THERAPY; TRIAL; ALPHA-2-INTERFERON;
Keywords:
HEPATOCELLULAR CARCINOMA; DOXORUBICIN; INTERFERON;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
42
Recensione:
Indirizzi per estratti:
Citazione:
J.P. Lotz et al., "TREATMENT OF UNRESECTABLE HEPATOCELLULAR-CARCINOMA WITH A COMBINATIONOF HUMAN RECOMBINANT ALPHA-2B INTERFERON AND DOXORUBICIN - RESULTS OFA PILOT-STUDY", European journal of cancer, 30A(9), 1994, pp. 1319-1325

Abstract

Based on the in vitro and in vivo potentiation of the cytotoxic activity of chemotherapeutic agents by the interferons, a pilot study combining human recombinant alpha-2b interferon (IFN) and doxorubicin was conducted for the treatment of unresectable, histologically proven hepatocellular carcinoma. Between March 1988 and May 1990, 21 patients (median age: 60 years, range: 29-76) entered the study. The dose of doxorubicin was fixed at 35 mg/m(2), every 3 weeks. The dose of alpha-2b IFN was 6 million U/m(2) per day, 5 days a week. 3 patients (14%) obtained a partial response lasting 11, 16 and 30 months, and 1 had a stabledisease during 8 months. The other 17 patients died within a median survival time of 4 months. All patients experienced flu-like symptoms. 7 patients experienced WHO grade III-IV haematological toxicity. We conclude that the association of alpha-2b IFN and doxorubicin is feasible, with respect to the use of doxorubicin at an inferior dose level than the same agent used without IFN. The response rate is comparable tothat observed with doxorubicin used alone. Further phase I studies and randomised trials are required to confirm the role of this regimen in the treatment of unresectable hepatocellular carcinoma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/12/20 alle ore 14:57:13